QuantX Biosciences

QuantX Biosciences is an emerging biotech leveraging advanced computational modeling and high-performance computing to accelerate the discovery of oral small molecule drugs. Founded in 2022 by veteran drug hunters and incubated by OrbiMed and Creacion Ventures, the company has rapidly built a pipeline targeting immunology and inflammation, with its lead programs advancing toward IND-enabling studies. The company recently secured an oversubscribed $85M Series B financing co-led by Sanofi Ventures and LAV, bringing its total funding to $130M, which will support clinical development of its STAT6 and IL-17 inhibitors.

Proprietary computational platform integrating accelerated long-term molecular dynamics simulation, physics-based modeling, statistical methods, and computational chemistry to design and optimize oral small molecule drug candidates.

QuantX competes in the crowded immunology and inflammation space, which includes major pharmaceutical companies with extensive resources and commercial portfolios (e.g., AbbVie, Johnson & Johnson, Amgen) and numerous biotech firms. Its direct competitors are other companies developing oral small molecules against targets like IL-17 and STAT6. QuantX's key differentiator is its proprietary computational platform, which aims to generate superior drug candidates with greater speed and efficiency than traditional discovery methods.